NovoCure Limited Profile Avatar - Palmy Investing

NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and G…

Medical - Instruments & Supplies
JE, Saint Helier [HQ]

Balance Sheet

11 Sheets · Starting from 2013
In Million USD. Margins, Growth Rates In %
Metric 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Assets
188.00 117.00 307.00 282.00 265.00 339.00 479.00 1,051.00 1,139.00 1,191.00 1,146.00
Current
183.00 111.00 293.00 261.00 245.00 321.00 439.00 999.00 1,073.00 1,111.00 1,034.00
Non Current
5.00 6.00 13.00 20.00 20.00 18.00 39.00 52.00 65.00 80.00 111.00
Liabilities
17.00 20.00 56.00 139.00 151.00 227.00 261.00 575.00 729.00 750.00 783.00
Current
15.00 17.00 28.00 36.00 50.00 64.00 86.00 113.00 142.00 158.00 179.00
Non Current
1.00 2.00 27.00 102.00 101.00 162.00 175.00 461.00 586.00 591.00 604.00
Equity
171.00 97.00 250.00 142.00 113.00 112.00 217.00 476.00 410.00 441.00 362.00
Stockholders' Equity
171.00 97.00 250.00 142.00 113.00 112.00 217.00 476.00 410.00 441.00 362.00
Retained Earnings
-195.00 -276.00 -388.00 -519.00 -582.00 -643.00 -650.00 -631.00 -685.00 -778.00 -985.00
Common Stock
- - - - - - - - - - - - - - - - - - - - - -
Preferred Stock
- - - - - - - - - - - - - - - - - - - - - -
Profit
-77.00 -80.00 -111.00 -131.00 -61.00 -63.00 -7.00 19.00 -58.00 -92.00 -207.00
Dividends
- - - - - - - - - - - - - - - - - - - - - -
Minority Interest
- - - - - - - - - - - - - - - - - - - - - -
Other Stockholders' Equity
370.00 378.00 640.00 664.00 697.00 757.00 871.00 1,111.00 1,099.00 1,222.00 1,353.00
Loss Other Compr. Income
-2.00 -4.00 -1.00 -1.00 -1.00 -1.00 -2.00 -3.00 -3.00 -2.00 -5.00
End of NVCR's Analysis
CIK: 1645113 CUSIP: G6674U108 ISIN: JE00BYSS4X48 LEI: - UEI: -
Secondary Listings
NVCR has no secondary listings inside our databases.